189 related articles for article (PubMed ID: 22451912)
1. PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas.
Baron BW; Anastasi J; Hyjek EM; Bies J; Reddy PL; Dong J; Joseph L; Thirman MJ; Wroblewski K; Wolff L; Baron JM
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5735-9. PubMed ID: 22451912
[TBL] [Abstract][Full Text] [Related]
2. GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas.
Baron BW; Anastasi J; Bies J; Reddy PL; Joseph L; Thirman MJ; Wroblewski K; Wolff L; Baron JM
Blood Cells Mol Dis; 2014 Jan; 52(1):68-75. PubMed ID: 23910958
[TBL] [Abstract][Full Text] [Related]
3. Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice.
Feldman BJ; Reid TR; Cleary ML
Oncogene; 1997 Nov; 15(22):2735-42. PubMed ID: 9401000
[TBL] [Abstract][Full Text] [Related]
4. The human BCL6 transgene promotes the development of lymphomas in the mouse.
Baron BW; Anastasi J; Montag A; Huo D; Baron RM; Karrison T; Thirman MJ; Subudhi SK; Chin RK; Felsher DW; Fu YX; McKeithan TW; Baron JM
Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14198-203. PubMed ID: 15375218
[TBL] [Abstract][Full Text] [Related]
5. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
[TBL] [Abstract][Full Text] [Related]
6. The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.
Baron BW; Baron RM; Baron JM
Biochim Biophys Acta; 2015 May; 1852(5):742-8. PubMed ID: 25557390
[TBL] [Abstract][Full Text] [Related]
7. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma.
Chaganti SR; Chen W; Parsa N; Offit K; Louie DC; Dalla-Favera R; Chaganti RS
Genes Chromosomes Cancer; 1998 Dec; 23(4):323-7. PubMed ID: 9824205
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
9. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
10. Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis.
Jardin F; Sahota SS
Hematology; 2005 Apr; 10(2):115-29. PubMed ID: 16019457
[TBL] [Abstract][Full Text] [Related]
11. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
Jardin F; Ruminy P; Bastard C; Tilly H
Pathol Biol (Paris); 2007 Feb; 55(1):73-83. PubMed ID: 16815642
[TBL] [Abstract][Full Text] [Related]
12. Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.
Batlle-López A; Cortiguera MG; Rosa-Garrido M; Blanco R; del Cerro E; Torrano V; Wagner SD; Delgado MD
Oncogene; 2015 Jan; 34(2):246-56. PubMed ID: 24362533
[TBL] [Abstract][Full Text] [Related]
13. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
Ueda C; Akasaka T; Kurata M; Maesako Y; Nishikori M; Ichinohasama R; Imada K; Uchiyama T; Ohno H
Oncogene; 2002 Jan; 21(3):368-76. PubMed ID: 11821949
[TBL] [Abstract][Full Text] [Related]
14. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma.
Chen YW; Hu XT; Liang AC; Au WY; So CC; Wong ML; Shen L; Tao Q; Chu KM; Kwong YL; Liang RH; Srivastava G
Blood; 2006 Oct; 108(7):2373-83. PubMed ID: 16772602
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal translocations involving BCL6 in MALT lymphoma.
Ye H; Remstein ED; Bacon CM; Nicholson AG; Dogan A; Du MQ
Haematologica; 2008 Jan; 93(1):145-6. PubMed ID: 18166802
[TBL] [Abstract][Full Text] [Related]
16. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.
Blyth K; Terry A; Mackay N; Vaillant F; Bell M; Cameron ER; Neil JC; Stewart M
Oncogene; 2001 Jan; 20(3):295-302. PubMed ID: 11313958
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
[TBL] [Abstract][Full Text] [Related]
18. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement.
Muramatsu M; Akasaka T; Kadowaki N; Ohno H; Yamabe H; Edamura S; Dor S; Mori T; Okuma M; Fukuhara S
Br J Haematol; 1996 Jun; 93(4):911-20. PubMed ID: 8703825
[TBL] [Abstract][Full Text] [Related]
19. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
20. The role of BCL6 in lymphomas and routes to therapy.
Wagner SD; Ahearne M; Ko Ferrigno P
Br J Haematol; 2011 Jan; 152(1):3-12. PubMed ID: 21083654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
